We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Technology Combines Speed of Rapid Antigen Test with Accuracy of PCR Testing to Detect COVID-19 in 4 Minutes

By LabMedica International staff writers
Posted on 10 Feb 2022
Print article
Illustration
Illustration

Scientists have developed a new coronavirus test that is accurate as a polymerase chain reaction (PCR) lab test but gives results within four minutes.

The test developed by researchers at Fudan University (Shanghai, China) uses a hypersensitive electromechanical biosensor to detect nucleic acids that were earlier difficult to identify owing to their low concentration in test samples. The sensor which uses microelectronics to analyze genetic material from swabs could reduce the need for time-consuming lab tests for diagnosing COVID-19.

PCR tests are the most accurate and sensitive for detecting SARS-COV-2, the virus that causes COVID-19, although they can take several hours to deliver results. Rapid antigen tests are a quicker alternative and deliver results in 15 minutes but are less reliable than PCR tests which are more accurate due to their greater sensitivity. In comparison to PCR tests, antigen tests require a higher concentration of the virus to exhibit a positive result due to which they are more likely to show a false negative. Antigen tests look for pieces of virus-infected proteins, while PCR tests search for viral genetic material such as nucleic acids and RNA.

Currently, there is no technology that can properly detect COVID-infected nucleic acids and RNA without using extraction and amplification methods which require a lab environment. The new method that uses a hypersensitive electromechanical biosensor to detect nucleic acids offers speed, ease of operation, high sensitivity and portability. Portable tests based on this technology could be used for on-site COVID-19 testing at airports, clinics, emergency departments and at home, as well as for quickly diagnosing other types of diseases.

In a clinical trial of the new test, the researchers collected nasal samples from 33 PCR-positive COVID-19 patients, 23 PCR-negative patients, six influenza-positive patients and 25 healthy volunteers. The researchers found that the test accurately processed all the cases without any errors in less than four minutes. The trial was conducted on a small sample, and if the 100% accuracy rate was replicated in a larger test sample, then the new test could be a game changer in COVID-19 diagnosis.

"We implemented an electromechanical biosensor for the detection of SARS-CoV-2 into an integrated and portable prototype device, and show that it detected (virus RNA) in less than four minutes," the team said in a peer-reviewed article describing their molecular electromechanical system, or MolEMS, in the journal Nature Biomedical Engineering.

Related Links:
Fudan University 

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.